Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6540
    +0.0017 (+0.26%)
     

  • OIL

    84.12
    +0.55 (+0.66%)
     

  • GOLD

    2,357.20
    +14.70 (+0.63%)
     

  • Bitcoin AUD

    98,573.41
    +373.55 (+0.38%)
     

  • CMC Crypto 200

    1,387.28
    -9.26 (-0.66%)
     

  • AUD/EUR

    0.6095
    +0.0022 (+0.36%)
     

  • AUD/NZD

    1.0975
    +0.0017 (+0.16%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,129.00
    +50.14 (+0.62%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    18,009.47
    +92.19 (+0.51%)
     

  • Hang Seng

    17,645.40
    +360.86 (+2.09%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Bellerophon Therapeutics, Inc.
·1-min read

WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.

The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company’s website at www.bellerophon.com.

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

Contacts

At W2O Group:

At LifeSci Advisors:

Julie Normart

Brian Ritchie

(559) 974-3245

(212) 915-2578

jnormart@w2ogroup.com

britchie@lifesciadvisors.com